Clinical Trials Logo

Metabolic Syndrome clinical trials

View clinical trials related to Metabolic Syndrome.

Filter by:

NCT ID: NCT05935904 Recruiting - Metabolic Syndrome Clinical Trials

Progression of Metabolic Syndrome Components During Pregnancy

MetS_Preg
Start date: June 27, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this cohort study is to investigate the underlying risk factors to develop metabolic syndrome (MetS) during pregnancy, and the associations of MetS and its indicators with birth outcomes in southwest Ethiopia. The study population consists of low-risk pregnant ladies in their first antenatal care visit (ANC), from Jimma Medical center. The main question[s] it aims to answer are: i) How do MetS components progress during pregnancy, and what are the underlying risk factors? ii) What is the association between MetS components during early- and late pregnancy and adverse pregnancy outcomes? iii) What is the knowledge, attitude and practices of women toward dietary habits, food taboos, and cultural beliefs during pregnancy? The study population consists of low-risk pregnant ladies in their first trimester (<15 weeks of pregnancy) in their first antenatal care visit (ANC) who will be followed up until one-month postpartum. Enrolled women will be assessed four times: at enrolment ≤15 weeks of pregnancy, mid-pregnancy (at 24 weeks), and late pregnancy (at 36 weeks), and within two weeks post-partum for: 1. Sociodemographic data 2. Dietary intake 3. Biochemical analyses 4. Maternal anthropometry: 5. Body composition in a subsample. 6. Knowledge, attitudes and practices of dietary practices during pregnancy 7. Pregnancy and birth outcomes: During the final visit, new born babies will be assessed for Apgar score, weight, length, and head circumference. The mother will be examined for general health and mode of delivery.

NCT ID: NCT05915117 Active, not recruiting - Metabolic Syndrome Clinical Trials

Effects of Polyphenols of Pomegranate Fruit Peel Extract on Inflammation and Oxidative Stress in Metabolic Syndrome

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effects of polyphenols of pomegranate fruit peel extract compared to placebo on oxidative stress and inflammation in overweight and obese subjects with metabolic syndrome.

NCT ID: NCT05911620 Recruiting - Metabolic Syndrome Clinical Trials

Evaluation of the Severity of Hepatic Fibrosis by Magnetic Resonance Elastography in the Diagnosis of Endogenous Hypercorticism

HEPACORT
Start date: October 24, 2023
Phase: N/A
Study type: Interventional

The main hypothesis of the HEPACORT study is that upon diagnosis of endogenous Cushing's syndrome, significant liver fibrosis may be present, particularly in the most severe forms of Cushing's syndrome. the HEPACORT study is the first exploratory study to assess the severity of liver fibrosis in patients with Cushing's syndrome or suspected of presenting by Magnetic Resonance Elastography (MRE).

NCT ID: NCT05910684 Completed - Clinical trials for Cardiometabolic Syndrome

Establishing Clinical Utility Evidence for Chronic Disease Management Testing Patient Study

Start date: July 19, 2022
Phase: N/A
Study type: Interventional

This is a national-level research study of primary care physicians. The purpose of this study is to assess the clinical evaluation and management (drug, procedures, counseling, and others) of a subset of common patient care indications.

NCT ID: NCT05908877 Not yet recruiting - Metabolic Syndrome Clinical Trials

Cardio-Metabolic Risk Evaluation in Overweight and Obese Children

CardMetSOb
Start date: July 10, 2023
Phase:
Study type: Observational

Metabolic and cardio-vascular complications can often appear in overweight and obese children from an early age. Currently, there are few studies in the specialized literature that correlate clinical, biological and ultrasound parameters in order to stratify cardio-metabolic risk in obese children. Also, the specialized literature is poor regarding longitudinal follow-up and the importance of diet for reducing metabolic and cardiovascular complications in these children. This study is designed to assess the hypothesis that the sustained improvement of lifestyle with regard to nutrition and exercise can reverse cardiometabolic multimorbidities in obese children as assessed by clinical, biological and ultrasound evaluation.

NCT ID: NCT05905965 Recruiting - Metabolic Syndrome Clinical Trials

Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment

DEMETER
Start date: May 1, 2023
Phase: Phase 3
Study type: Interventional

The DEMETER - SIRIO 11 study is a phase III, multicenter, randomized, open-labled, investigator-initiated clinical trial with a 6 month follow-up. The study population will include 200 subjects with diagnosis of metabolic syndrome. All enrolled patients (nn=200) will be randomly assigned in 1:1 ratio to one of the two study arms: 1. Empagliflozin 20 mg - experimental arm 2. Empagliflozin 10 mg - control arm. Primary co-endpoints of the study include: BMI and HbA1c. Secondary endpoints include: LDL-C, triglycerides, CRP, NT-proBNP, LVEF (echocardiography), body composition, VO2max (ergospirometry), waist-hip ratio (WHR), liver steatosis assessment (LSA) by computed tomography (CT), major adverse cardiovascular events - MACE (based on medical history: heart attack, stroke, death), cardiovascular hospitalizations.

NCT ID: NCT05903950 Recruiting - Metabolic Syndrome Clinical Trials

Air Pollution and Cardiovascular Disease in Qatar: an Interventional Study to Reduce Blood Pressure

APCIQ-BP
Start date: June 2024
Phase: N/A
Study type: Interventional

The main objective is to determine if in-home portable air cleaners provide persistent reductions in PM2.5 exposures and improvements in systolic blood pressure and biochemical parameters over 4-weeks in patients with metabolic syndrome residing in Qatar.

NCT ID: NCT05899309 Recruiting - Metabolic Syndrome Clinical Trials

Precision Medicine to Predict the Trajectory of Liver Cirrhosis: Prospective Cohort Study

Start date: May 23, 2022
Phase:
Study type: Observational

Preventing decompensation is a key endpoint in the management of compensate cirrhosis patients. The known factors that increases the risk of decompensation include the presence of clinically significant portal hypertension (CSPH) and the control of primary etiology of cirrhosis. Other factors which may influence the progression of cirrhosis included the presence of metabolic syndrome (diabetes mellitus and obesity), frailty, concomitant medications (statin, non-selective beta-blocker) were not well understood. Investigators aim to perform a pilot, observational study to study various baseline factors in relation to the clinical outcome of cirrhosis patients in a prospective follow up.

NCT ID: NCT05898360 Recruiting - HEALTHY VOLUNTEERS Clinical Trials

Promoting Immune Health by Intermittent Fasting: a Pilot Study

TIGER
Start date: May 15, 2023
Phase: N/A
Study type: Interventional

The goal is to study the direct effects of long-term intermittent fasting on immune cell populations in the blood, combined with analyses of systemic metabolic fitness and inflammatory activation of leukocytes.

NCT ID: NCT05897073 Recruiting - Obesity Clinical Trials

Time-Restricted Eating, Exercise and Cardiometabolic Health in Obesity

TEMPUS
Start date: May 2, 2023
Phase: N/A
Study type: Interventional

In Spain, overweight and obesity prevalence is reaching 70% in men and 50% in women. Excess of triglycerides are usually stored in the subcutaneous adipose tissue (SAT), until a point where SAT is unable to expand further. Therefore, lipids are deposited in visceral and other peripheral organs and tissues that are not otherwise designed for adipose storage such as the liver, pancreas or the skeletal muscle, a process known as ectopic fat deposition. "Time-restricted eating" (TRE) is a recently emerged intermittent fasting approach which has the potential to maximize the beneficial metabolic effects extensively reported for energy intake restriction. Furthermore, exercise reduces hepatic steatosis and improves cardiometabolic health in humans. However, whether the effects of TRE combined with exercise on reducing hepatic steatosis are superior to TRE or exercise intervention alone remains unknown. The TEMPUS study will investigate the effects of a 12-week TRE combined with supervised exercise intervention, as compared with TRE or exercise alone, and usual-care control group, on hepatic fat (primary outcome) and cardiometabolic health (secondary outcomes) in adults with obesity; and to unveil the role of gut microbiota.